← Back

UK MHRA · UK · 18 Nov 2026 · News & press

MHRA AdvanceGxP service: building compliance into innovation earlier

AI-generated summary

The MHRA is developing AdvanceGxP, a new service to help organisations developing novel medicines technologies understand Good Practice requirements earlier in development, reducing regulatory uncertainty while maintaining independent decision-making. Initially focusing on disruptive innovation in medicines manufacturing, the service will provide practical regulatory expertise to help organisations identify compliance issues before key development and investment decisions are fixed. AdvanceGxP is not yet open for applications; the MHRA is currently testing and piloting early phases with no charges during development. Organisations developing novel or potentially disruptive medicines technologies can register their interest to help test the service.

From UK MHRA

A new MHRA service being developed to help organisations working on novel medicines technologies consider Good Practice requirements earlier.

AdvanceGxP is a new MHRA service being developed to help organisations working on novel medicines technologies consider Good Practice requirements earlier, reducing regulatory uncertainty while maintaining independent regulatory and inspection decision-making.

Developed with the Office for Life Sciences, AdvanceGxP will initially focus on disruptive innovation in medicines manufacturing. As the service develops, it will explore how earlier, practical and principles-based regulatory support can help innovators make better-informed decisions before critical development, manufacturing and investment choices are fixed.

The need for AdvanceGxP

Innovation in medicines and advanced manufacturing is moving quickly. For organisations developing emerging technologies, there may be limited precedent, detailed guidance or case studies showing how established Good Practice principles will apply. This can create uncertainty at precisely the point when important decisions about facilities, processes, validation and investment are being made.

AdvanceGxP is being developed to help close that gap

By bringing regulatory and compliance thinking into development earlier, AdvanceGxP aims to help organisations understand relevant Good Practice principles, identify potential issues and build compliance into innovation from the outset. This can help organisations make better-informed decisions and manage regulatory and compliance risks within their own development programmes.

Earlier access to practical Good Practice expertise

When fully operational, AdvanceGxP will provide earlier access to practical, regulator-led Good Practice expertise for organisations developing novel and potentially disruptive medicines technologies. The service is being designed to:

- help organisations explore how Good Practice principles may apply to emerging technologies

- support earlier consideration of compliance, before key development decisions are fixed

- provide practical regulatory and compliance insight

- connect seamlessly with wider MHRA services and regulatory pathways.

AdvanceGxP will complement existing MHRA services and formal inspection. It will not be an inspection or pre-inspection clearance, prescribe a particular technical solution, or guarantee a future regulatory or inspection outcome.

Developing the service

AdvanceGxP is not yet open for applications. We are currently developing the service, including eligibility criteria and how organisations will access support.

Testing and piloting early phases

The initial focus will be deliberately limited while we test demand, capacity, user experience and the types of support that provide most value.

Fees and charges

Excerpt from the official page. The original is authoritative. Continue reading at UK MHRA ↗